吡咯烷-1-丁酸甲酯 | 22041-24-3

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 中文名称: 吡咯烷-1-丁酸甲酯
• 英文名称: methyl 4-(pyrrolidin-1-yl)butyrate
• 英文别名: Methyl pyrrolidine-1-butyrate；methyl 4-pyrrolidin-1-ylbutanoate
• CAS: 22041-24-3
• 化学式: C₉H₁₇NO₂
• 分子量: 171.239
• InChiKey: YUWSENDKBFKEMK-UHFFFAOYSA-N

物化性质

• 沸点：
  238.5±23.0 °C(Predicted)
• 密度：
  1.005±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  12
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.89
• 拓扑面积：
  29.5
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  吡咯烷-1-丁酸甲酯 在 potassium hydroxide 、 氯化亚砜 作用下， 以 甲醇 、 水 、 乙醇 为溶剂， 反应 6.0h， 以36.5 g的产率得到4-(pyrrolidin-1-yl)butanoyl chloride
  参考文献：
  名称：

  盐酸丁咯地尔的制备方法

  摘要：

  本发明盐酸丁咯地尔的制备方法涉及药物生产领域，具体涉及盐酸丁咯地尔的制备方法，包括以下步骤：l‑吡咯烷基丁酸甲酯的合成，在干燥反应瓶中投入68.3g4‑氯丁酸甲酯、无水碳酸钾82.8g、碘化钾0.2g、吡咯烷39.1g、丙酮500mL，加热至回流反应3h后，将反应液冷却至室温后滤除碳酸钾，滤液减压至干后加入二氯甲烷500mL溶解，再用饱和氯化铵水溶液洗涤有机相至pH为7～8，有机相经无水硫酸镁干燥后浓缩去除二氯甲烷得浓缩物，将浓缩物减压蒸馏收集107‑109度馏分得l‑吡咯烷基丁酸甲酯80.1g；本发明工艺简单，反应安全，合成路线短，原料易得，条件温和，成本更低廉。

  公开号：

  CN107698539A
• 作为产物：
  描述：

  四氢吡咯 、 4-氯丁酸甲酯 在 potassium carbonate 、 potassium iodide 作用下， 以 丙酮 为溶剂， 反应 3.0h， 以80.1 g的产率得到吡咯烷-1-丁酸甲酯
  参考文献：
  名称：

  盐酸丁咯地尔的制备方法

  摘要：

  本发明盐酸丁咯地尔的制备方法涉及药物生产领域，具体涉及盐酸丁咯地尔的制备方法，包括以下步骤：l‑吡咯烷基丁酸甲酯的合成，在干燥反应瓶中投入68.3g4‑氯丁酸甲酯、无水碳酸钾82.8g、碘化钾0.2g、吡咯烷39.1g、丙酮500mL，加热至回流反应3h后，将反应液冷却至室温后滤除碳酸钾，滤液减压至干后加入二氯甲烷500mL溶解，再用饱和氯化铵水溶液洗涤有机相至pH为7～8，有机相经无水硫酸镁干燥后浓缩去除二氯甲烷得浓缩物，将浓缩物减压蒸馏收集107‑109度馏分得l‑吡咯烷基丁酸甲酯80.1g；本发明工艺简单，反应安全，合成路线短，原料易得，条件温和，成本更低廉。

  公开号：

  CN107698539A

文献信息

• [EN] ALPHA7 NICOTINIC ACETYLCHOLINE RECEPTOR INHIBITORS<br/>[FR] INHIBITEURS DE RÉCEPTEURS NICOTINIQUES ALPHA-7 DE L'ACÉTYLCHOLINE
  申请人：WYETH CORP

  公开号：WO2010009290A1

  公开（公告）日：2010-01-21

  The present invention provides compounds and compositions, methods of making them, and methods of using them to modulate α7 nicotinic acetylcholine receptors and/or to treat any of a variety of disorders, diseases, and conditions. Provided compounds can affect, among other things, neurological, psychiatric and/or inflammatory systems.

  本发明提供了化合物和组合物，制备它们的方法，以及利用它们调节α7烟碱乙酰胆碱受体和/或治疗各种疾病、疾病和症状的方法。所提供的化合物可以影响神经系统、精神病学和/或炎症系统等方面。
• NOVEL SULFONATE AND ITS DERIVATIVE, PHOTOSENSITIVE ACID GENERATOR, AND RESIST COMPOSITION AND PATTERNING PROCESS USING THE SAME
  申请人：OHASHI Masaki

  公开号：US20100209827A1

  公开（公告）日：2010-08-19

  There is disclosed a sulfonate shown by the following general formula (2). R 1 —COOC(CF 3 ) 2 —CH 2 SO 3 − M + (2) (In the formula, R 1 represents a linear, a branched, or a cyclic monovalent hydrocarbon group having 1 to 50 carbon atoms optionally containing a hetero atom. M + represents a cation.) There can be provided: a novel sulfonate which is effective for a chemically amplified resist composition having a sufficiently high solubility (compatibility) in a resist solvent and a resin, a good storage stability, a PED stability, a further wider depth of focus, a good sensitivity, in particular a high resolution and a good pattern profile form; a photosensitive acid generator; a resist composition using this; a photomask blank, and a patterning process.

  本发明揭示了一种磺酸盐，其通式如下（2）所示。 R1-COOC（CF3）2-CH2SO3-M+（2）（其中，R1表示具有1至50个碳原子的线性、分支或环状单价碳氢基团，可选含有杂原子。M+表示一个阳离子）。本发明可以提供：一种新型磺酸盐，其在抗蚀剂溶剂和树脂中具有足够高的溶解度（相容性），良好的储存稳定性，PED稳定性，进一步扩大焦点深度，良好的灵敏度，特别是高分辨率和良好的图案轮廓形态；一种光敏酸发生剂；使用该组合物的抗蚀剂组合物；一种光掩膜空白，以及一种制图工艺。
• Heterocyclic esters of benzopyrans
  申请人：Sharps Associates

  公开号：US03941782A1

  公开（公告）日：1976-03-02

  This invention relates to novel esters of benzopyrans represented by the formulae ##SPC1## Wherein R and R' are hydrogen or C.sub.1 -C.sub.6 alkyl and when alkyl are on the same or different carbons; R.sub.1 is C.sub.1 -C.sub.6 alkyl; R.sub.2 is C.sub.1 -C.sub.20 alkyl, lowercycloalkyloweralkyl or lowercycloalkyl; n is an integer from 3 to 7, and particularly 3 to 5; Y is a straight or branched chain C.sub.1 -C.sub.8 alkylene; and R.sub.3 is ##EQU1## WHEREIN A IS AN INTEGER FROM 1 TO 4, B IS AN INTEGER FROM 1 TO 4, X is O,S, CH.sub.2 or NR.sub.4 and R.sub.4 is hydrogen C.sub.1 -C.sub.6 alkyl, and R.sub.5 is hydrogen or C.sub.1 -C.sub.6 alkyl; and the acid addition salts thereof. The compounds exhibit analgesic and central nervous system activity.

  本发明涉及一种新型苯并吡喃酸酯，其化学式为：##SPC1## 其中，R和R'为氢或C.sub.1-C.sub.6烷基，当烷基在同一或不同碳上时；R.sub.1为C.sub.1-C.sub.6烷基；R.sub.2为C.sub.1-C.sub.20烷基，较低的环烷基较低的烷基或较低的环烷基；n为3至7的整数，特别是3至5；Y为直链或支链C.sub.1-C.sub.8烷基；R.sub.3为##EQU1## 其中，A为1至4的整数，B为1至4的整数，X为O、S、CH.sub.2或NR.sub.4，R.sub.4为氢C.sub.1-C.sub.6烷基，R.sub.5为氢或C.sub.1-C.sub.6烷基；以及其酸盐加合物。这些化合物表现出镇痛和中枢神经系统活性。
• Heterocyclic esters of alkylphenyl benzopyrans
  申请人：Abbott Laboratories

  公开号：US04049653A1

  公开（公告）日：1977-09-20

  Heterocyclic esters of benzopyrans represented by the formula ##STR1## wherein n is 1 or 2; each R and R.sub.1 are the same or different members of the group consisting of hydrogen or loweralkyl; R.sub.2 is loweralkyl; R.sub.3 is ##STR2## WITH Y' being a straight or branched chain alkylene group having from one to eight carbon atoms, a is an integer from 1 to 4, b is an integer from 1 to 4, X is CH.sub.2, O, S or NR.sub.7 with R.sub.7 being hydrogen or loweralkyl, with the limitation that when X is O, S, or NR.sub.7, a and b each must be 2; R.sub.8 is hydrogen or loweralkyl; Y is a straight or branched chain alkylene group having from one to ten carbon atoms; and each R.sub.4 and R.sub.5 and R.sub.6 are the same or different members of the group consisting of hydrogen, halo, trifluoromethyl or loweralkyl; and the pharmaceutically acceptable salts thereof.

  苯并吡喃的杂环酯化合物的化学式为##STR1## 其中n为1或2；每个R和R.sub.1是氢或低碳烷基的相同或不同成员；R.sub.2是低碳烷基；R.sub.3是##STR2## 其中Y'是一条直链或支链烷基，其具有1至8个碳原子，a是1至4的整数，b是1至4的整数，X是CH.sub.2、O、S或NR.sub.7，其中R.sub.7为氢或低碳烷基，但当X为O、S或NR.sub.7时，a和b必须各为2；R.sub.8是氢或低碳烷基；Y是一条直链或支链烷基，其具有1至10个碳原子；每个R.sub.4、R.sub.5和R.sub.6是氢、卤素、三氟甲基或低碳烷基的相同或不同成员；以及其药学上可接受的盐。
• Anesthesia methods using benzopyrans and esters thereof as
  申请人：Abbott Laboratories

  公开号：US04025630A1

  公开（公告）日：1977-05-24

  Improved anesthesia methods comprising pretreating a patient to be anesthetized with a benzopyran of formula I ##STR1## wherein, in the C ring, X is NR.sub.1, S, CH.sub.2 or ##STR2## R.sub.1 is hydrogen, loweralkyl, loweralkenyl, loweralkynyl, loweralkanoyl, cycloalkyloweralkyl, cycloalkylloweralkanoyl, cycloalkyl, haloloweralkyl, haloloweralkenyl, phenylloweralkyl, phenyloweralkenyl or phenyloweralkylnyl; m is an integer from 0 to 3, n is an integer from 0 to 3 and n + m = 2 or 3; or the C ring is quinuclidine ring ##STR3## R.sub.2 is loweralkyl; R.sub.3 is hydrogen or ##STR4## wherein Y is a straight or branched chain alkylene group having from one to eight carbon atoms, a is an integer from 1 to 4, b is an integer from 1 to 4, Z is CH.sub.2, O, S or NR.sub.6, R.sub.6 being hydrogen or loweralkyl, with the limitation that when Z is O, S or NR.sub.5, the sum of a and b is 3 or 4, and R.sub.5 is hydrogen or loweralkyl; R.sub.4 is C.sub.1 -C.sub.20 straight or branched chain alkyl, cycloalkyl, or ##STR5## wherein Y is a straight or branched chain alkylene group having from one to ten carbon atoms, and each R.sub.7, R.sub.8 and R.sub.9 are the same or different members of the group consisting of hydrogen, halo, trifluoromethyl or loweralkyl; and the pharmaceutically acceptable salts thereof, with the limitation that when X is ##STR6## m = 2 and n = 2, R.sub.3 cannot be hydrogen.

  改进的麻醉方法包括使用式I的苯并吡喃预处理待麻醉的患者，其中在C环中，X为NR.sub.1，S，CH.sub.2或##STR2##，R.sub.1为氢，低烷基，低烯基，低炔基，低酰基，环烷基低烷基，环烷基低酰基，环烷基，卤代低烷基，卤代低烯基，苯基低烷基，苯基低烯基或苯基低烷基基；m为0至3的整数，n为0至3的整数，n + m = 2或3；或C环为喹啉环##STR3##，R.sub.2为低烷基；R.sub.3为氢或##STR4##，其中Y为直链或支链烷基链，具有1至8个碳原子，a为1至4的整数，b为1至4的整数，Z为CH.sub.2，O，S或NR.sub.6，其中R.sub.6为氢或低烷基，限制条件为当Z为O，S或NR.sub.5时，a和b的和为3或4，R.sub.5为氢或低烷基；R.sub.4为C.sub.1-C.sub.20直链或支链烷基，环烷基，或##STR5##，其中Y为具有1至10个碳原子的直链或支链烷基链，每个R.sub.7，R.sub.8和R.sub.9是相同或不同的羟基，卤素，三氟甲基或低烷基成员的群；及其药学上可接受的盐，限制条件为当X为##STR6##时，m = 2且n = 2时，R.sub.3不能为氢。